K. Drlica

发表

Reactive oxygen species and the bacterial response to lethal stress.

Xilin Zhao, K. Drlica, 2014, Current opinion in microbiology.

Is ‘dosing-to-cure’ appropriate in the face of antimicrobial resistance?

Xilin Zhao, K. Drlica, 2004 .

Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones

Xilin Zhao, K. Drlica, M. Malik, 2006, Molecular microbiology.

Mutation in the DNA Gyrase A Gene ofEscherichia coli That Expands the Quinolone Resistance-Determining Region

S. M. Friedman, K. Drlica, S. Friedman, 2001, Antimicrobial Agents and Chemotherapy.

Gatifloxacin Activity against Quinolone-Resistant Gyrase: Allele-Specific Enhancement of Bacteriostatic and Bactericidal Activities by the C-8-Methoxy Group

Xilin Zhao, K. Drlica, T. Lu, 1999, Antimicrobial Agents and Chemotherapy.

Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae

J. Blondeau, Xilin Zhao, K. Drlica, 2001, Antimicrobial Agents and Chemotherapy.

The Changing Face of Antibiotic Prescribing: The Mutant Selection Window

J. Gums, K. Drlica, B. Epstein, 2004, The Annals of pharmacotherapy.

In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus

K. Drlica, S. Zinner, A. Firsov, 2003, Antimicrobial Agents and Chemotherapy.

Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.

Xilin Zhao, K. Drlica, R. Kerns, 2006, The Journal of antimicrobial chemotherapy.

Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones

K. Drlica, M. Malik, N. German, 2008, Antimicrobial Agents and Chemotherapy.

Novel Approach for Comparing the Abilities of Quinolones To Restrict the Emergence of Resistant Mutants during Quinolone Exposure

K. Drlica, K. Chavda, M. Malik, 2009, Antimicrobial Agents and Chemotherapy.

Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?

B. Kreiswirth, Xilin Zhao, K. Drlica, 2004, International journal of antimicrobial agents.

Fluoroquinolone-Resistant Streptococcus agalactiae: Epidemiology and Mechanism of Resistance

K. Drlica, S. Segal-Maurer, C. Urban, 2005, Antimicrobial Agents and Chemotherapy.

Susceptibility of Cutibacterium acnes to topical minocycline foam.

I. Stuart, K. Drlica, J. Sutcliffe, 2020, Anaerobe.

Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Xilin Zhao, K. Drlica, 2002, The Journal of infectious diseases.

Fluoroquinolone Action against Clinical Isolates ofMycobacterium tuberculosis: Effects of a C-8 Methoxyl Group on Survival in Liquid Media and in Human Macrophages

J. Domagala, R. Pine, K. Drlica, 1999, Antimicrobial Agents and Chemotherapy.

Role of Superoxide in Catalase-Peroxidase-Mediated Isoniazid Action against Mycobacteria

K. Drlica, R. Burger, Jian‐ying Wang, 1998, Antimicrobial Agents and Chemotherapy.

Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis.

J. Musser, S. Sreevatsan, B. Kreiswirth, 1996, The Journal of infectious diseases.

Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates ofMycobacterium tuberculosis

B. Kreiswirth, Xilin Zhao, K. Drlica, 2000, Antimicrobial Agents and Chemotherapy.

Mutant Selection Window Hypothesis: A Framework for Anti-mutant Dosing of Antimicrobial Agents

Xilin Zhao, K. Drlica, 2008 .

Moxifloxacin Lethality against Mycobacterium tuberculosis in the Presence and Absence of Chloramphenicol

K. Drlica, M. Malik, Muhammad Malik, 2006, Antimicrobial Agents and Chemotherapy.

Fluoroquinolones as imaging agents for bacterial infection.

K. Drlica, S. A. Naqvi, 2017, Dalton transactions.

Heteroresistance: A Harbinger of Future Resistance

Xilin Zhao, K. Drlica, B. Shopsin, 2018 .

Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Xilin Zhao, K. Drlica, X. Zhao, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mechanisms of Fluoroquinolone Action and Resistance

K. Drlica, 2000 .

A unified anti-mutant dosing strategy.

Xilin Zhao, K. Drlica, 2008, The Journal of antimicrobial chemotherapy.

The mutant selection window in rabbits infected with Staphylococcus aureus.

Xilin Zhao, K. Drlica, You-ning Liu, 2006, The Journal of infectious diseases.

A broadly applicable, stress-mediated bacterial death pathway regulated by the phosphotransferase system (PTS) and the cAMP-Crp cascade

Xilin Zhao, K. Drlica, Yuzhi Hong, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus

B. Kreiswirth, Xilin Zhao, K. Drlica, 2003, Antimicrobial Agents and Chemotherapy.

Diabetes as a compounding factor in COVID-19-mediated male subfertility

K. Drlica, T. Linn, Lanbo Shi, 2021 .

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Xilin Zhao, K. Drlica, G. Tillotson, 2002, The New England journal of medicine.

Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

J. Blondeau, K. Drlica, K. Metzler, 2013, The Journal of antimicrobial chemotherapy.

Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection

Sanjay Tyagi, I. Kurland, Y. Qiu, 2022, mBio.

Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin

Xilin Zhao, K. Drlica, Xinying Li, 2002, Antimicrobial Agents and Chemotherapy.

Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics.

J. Berger, Liping Li, Xilin Zhao, 2014, The Journal of antimicrobial chemotherapy.

Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance.

Xinjing Wang, Xilin Zhao, K. Drlica, 2005, The Journal of antimicrobial chemotherapy.

Quinolone-Resistant Haemophilus influenzae: Determination of Mutant Selection Window for Ciprofloxacin, Garenoxacin, Levofloxacin, and Moxifloxacin

K. Drlica, C. Urban, J. Rahal, 2004, Antimicrobial Agents and Chemotherapy.

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.

J. Blondeau, Xilin Zhao, K. Drlica, 2006, International journal of antimicrobial agents.

Bleomycin Reaction Pathways: Kinetic Approaches

K. Drlica, R. Burger, 1996 .

In Vitro Model of Mycobacterial Growth Arrest Using Nitric Oxide with Limited Air

M. Gennaro, K. Drlica, Lanbo Shi, 2008, Antimicrobial Agents and Chemotherapy.

Effect of N-1/C-8 Ring Fusion and C-7 Ring Structure on Fluoroquinolone Lethality

Kevin R. Marks, K. Drlica, M. Malik, 2010, Antimicrobial Agents and Chemotherapy.

Lon Protease Is Essential for Paradoxical Survival of Escherichia coli Exposed to High Concentrations of Quinolone

K. Drlica, M. Malik, Joseph Capecci, 2009, Antimicrobial Agents and Chemotherapy.

Effect of Anaerobic Growth on Quinolone Lethality with Escherichia coli

K. Drlica, M. Malik, S. Hussain, 2006, Antimicrobial Agents and Chemotherapy.

Lethal Action of Quinolones against a Temperature-Sensitive dnaB Replication Mutant of Escherichia coli

A. Drlica-Wagner, Xilin Zhao, K. Drlica, 2006, Antimicrobial Agents and Chemotherapy.

Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species

N. Chandra, H. Chakrapani, Amit Singh, 2022, Antimicrobial agents and chemotherapy.

Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement

Ashutosh Kumar Singh, Xilin Zhao, K. Drlica, 2022, Frontiers in Cellular and Infection Microbiology.

Fluoroquinolones: action and resistance.

K. Drlica, M. Malik, Muhammad Malik, 2003, Current topics in medicinal chemistry.

Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.

Kevin R. Marks, K. Drlica, H. Hiasa, 2011, Bioorganic & medicinal chemistry letters.

Fluoroquinolone-resistant Streptococcus pneumoniae

Xilin Zhao, K. Drlica, 2003 .

gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.

J. Heddle, A. Maxwell, Xilin Zhao, 2001, Journal of molecular biology.

Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis

D. Hooper, Xilin Zhao, K. Drlica, 2000, Antimicrobial Agents and Chemotherapy.

Killing of Staphylococcus aureus by C-8-Methoxy Fluoroquinolones

J. Domagala, Xilin Zhao, K. Drlica, 1998, Antimicrobial Agents and Chemotherapy.

Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.

Xilin Zhao, K. Drlica, S. Zinner, 2003, The Journal of antimicrobial chemotherapy.

Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus.

Xilin Zhao, K. Drlica, M. Malik, 2007, The Journal of antimicrobial chemotherapy.

Lethality of Quinolones against Mycobacterium smegmatis in the Presence or Absence of Chloramphenicol

J. Domagala, Xilin Zhao, K. Drlica, 2005, Antimicrobial Agents and Chemotherapy.

Oxygen isotope effect on activated bleomycin stability

K. Drlica, R. Burger, G. Tian, 1995 .

Fluoroquinolone and Quinazolinedione Activities against Wild-Type and Gyrase Mutant Strains of Mycobacterium smegmatis

Kevin R. Marks, Xilin Zhao, K. Drlica, 2011, Antimicrobial Agents and Chemotherapy.

Quinolones: Action and Resistance Updated

Xilin Zhao, K. Drlica, H. Hiasa, 2009, Current topics in medicinal chemistry.

Quinolone-Mediated Bacterial Death

Xilin Zhao, Xilin Zhao, K. Drlica, 2007, Antimicrobial Agents and Chemotherapy.

Fluoroquinolone Action against Mycobacteria: Effects of C-8 Substituents on Growth, Survival, and Resistance

J. Domagala, Xilin Zhao, K. Drlica, 1998, Antimicrobial Agents and Chemotherapy.

The future of fluoroquinolones

K. Drlica, 2000, Annals of medicine.

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

J. Domagala, Xilin Zhao, K. Drlica, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.

K. Drlica, C. Urban, J. Rahal, 2001, The Journal of infectious diseases.

Mechanism of fluoroquinolone action.

K. Drlica, K Drlica, 1999, Current opinion in microbiology.

Fluoroquinolone Resistance: Mechanisms, Restrictive Dosing, and Anti-Mutant Screening Strategies for New Compounds

Xilin Zhao, K. Drlica, T. Salz, 2012 .

Mechanisms of Quinolone Action

D. Hooper, K. Drlica, 2003 .

The mutant selection window and antimicrobial resistance.

K. Drlica, 2003, The Journal of antimicrobial chemotherapy.

Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus

A. Drlica-Wagner, J. Domagala, Xilin Zhao, 2001, Antimicrobial Agents and Chemotherapy.

Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes.

K. Drlica, G. Tillotson, X. Zhao, 2001, The Lancet. Infectious diseases.

Sequential evolution of virulence and resistance during clonal spread of community-acquired methicillin-resistant Staphylococcus aureus

R. Sebra, H. van Bakel, R. Copin, 2019, Proceedings of the National Academy of Sciences.

Moving forward with reactive oxygen species involvement in antimicrobial lethality.

Xilin Zhao, K. Drlica, Yuzhi Hong, 2015, The Journal of antimicrobial chemotherapy.

Escherichia coli genes that reduce the lethal effects of stress

Xilin Zhao, K. Drlica, M. Malik, 2010, BMC Microbiology.

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.

J. Blondeau, K. Drlica, K. Metzler, 2004, International journal of antimicrobial agents.

Reemergence of Established Pathogens in the 21st Century

I. Fong, K. Drlica, M. Morosini, 2013, Emerging Infectious Diseases of the 21st Century.

Bypassing Fluoroquinolone Resistance with Quinazolinediones: Studies of Drug–Gyrase–DNA Complexes Having Implications for Drug Design

J. Berger, K. Drlica, R. Kerns, 2014, ACS chemical biology.

Mutant selection window hypothesis updated.

Xilin Zhao, K. Drlica, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low Correlation between MIC and Mutant Prevention Concentration

J. Blondeau, Xilin Zhao, K. Drlica, 2006, Antimicrobial Agents and Chemotherapy.

Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria

J. Domagala, A. Liew, Xilin Zhao, 2000, Antimicrobial Agents and Chemotherapy.

Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG andStaphylococcus aureus

J. Domagala, Xilin Zhao, K. Drlica, 1999, Antimicrobial Agents and Chemotherapy.

Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.

J. Musser, J. Domagala, Xilin Zhao, 2000, The Journal of infectious diseases.

Moxifloxacin-mediated killing of Mycobacterium tuberculosis involves respiratory downshift, reductive stress, and ROS accumulation

N. Chandra, H. Chakrapani, Amit Singh, 2022, bioRxiv.

Controlling Antibiotic Resistance: Strategies Based on the Mutant Selection Window

Xilin Zhao, K. Drlica, 2004 .

Therapeutic options in an era of decreasing antimicrobial susceptibility.

K. Drlica, F. Schmitz, 2002, Journal of chemotherapy.

Cytotoxic hammerhead ribozymes.

R. Levitz, K. Drlica, J. Y. Wang, 1999, Antisense & nucleic acid drug development.

Quinolone-Resistant Haemophilus influenzae in a Long-Term-Care Facility: Nucleotide Sequence Characterization of Alterations in the Genes Encoding DNA Gyrase and DNA Topoisomerase IV

K. Drlica, C. Urban, J. Rahal, 2004, Antimicrobial Agents and Chemotherapy.

Ribosomal Elongation Factor 4 Promotes Cell Death Associated with Lethal Stress

Liping Li, Xilin Zhao, K. Drlica, 2014, mBio.

Reactive oxygen species play a dominant role in all pathways of rapid quinolone-mediated killing.

Xilin Zhao, K. Drlica, Jianping Xie, 2019, The Journal of antimicrobial chemotherapy.

Diabetes as a potential compounding factor in COVID-19-mediated male subfertility

K. Drlica, T. Linn, Lanbo Shi, 2022, Cell & Bioscience.

Gain-of-Function Mutations in Acid Stress Response (evgS) Protect Escherichia coli from Killing by Gallium Nitrate, an Antimicrobial Candidate

Jiabin Li, Xilin Zhao, K. Drlica, 2020, Antimicrobial Agents and Chemotherapy.

Antimicrobial Resistance in the 21st Century

I. Fong, K. Drlica, D. Shlaes, 2018, Emerging Infectious Diseases of the 21st Century.

Post-stress bacterial cell death mediated by reactive oxygen species

Xilin Zhao, K. Drlica, Yuzhi Hong, 2019, Proceedings of the National Academy of Sciences.

Bacterial death from treatment with fluoroquinolones and other lethal stressors

Xilin Zhao, K. Drlica, 2020, Expert review of anti-infective therapy.

Contribution of Reactive Oxygen Species to Thymineless Death in Escherichia coli

Liping Li, Xilin Zhao, K. Drlica, 2017, Nature Microbiology.

Antimicrobial-Mediated Bacterial Suicide

Xilin Zhao, K. Drlica, Yuzhi Hong, 2018 .

YihE kinase is a central regulator of programmed cell death in bacteria.

Xilin Zhao, K. Drlica, T. Salz, 2013, Cell reports.

Antibiotic resistance: can we beat the bugs?

K. Drlica, 2001, Drug discovery today.

The DNA cleavage pathway of iron bleomycin. Strand scission precedes deoxyribose 3-phosphate bond cleavage.

K. Drlica, R. Burger, B. Birdsall, 1994, The Journal of biological chemistry.

Fluoroquinolone-Gyrase-DNA Complexes

Kevin R. Marks, J. Berger, Xilin Zhao, 2014, The Journal of Biological Chemistry.

Tuning of the Lethal Response to Multiple Stressors with a Single-Site Mutation during Clinical Infection by Staphylococcus aureus

K. Drlica, B. Shopsin, John Chen, 2017, mBio.

Fluoroquinolone Resistance

Xilin Zhao, K. Drlica, H. Hiasa, 2019, Bacterial Resistance to Antibiotics – From Molecules to Man.

Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration

Xilin Zhao, K. Drlica, Yuzhi Hong, 2017, Antimicrobial Agents and Chemotherapy.

Superoxide-Mediated Protection of Escherichia coli from Antimicrobials

Liping Li, Xilin Zhao, K. Drlica, 2013, Antimicrobial Agents and Chemotherapy.

A Toxin-Antitoxin Module in Bacillus subtilis Can Both Mitigate and Amplify Effects of Lethal Stress

Xilin Zhao, K. Drlica, Xiangli Wu, 2011, PloS one.

Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death.

Xilin Zhao, K. Drlica, M. Malik, 2010, The Journal of antimicrobial chemotherapy.

Antimicrobial resistance and implications for the 21st century

I. Fong, K. Drlica, 2008 .

An Anti-mutant Approach for Antimicrobial Use

Xilin Zhao, K. Drlica, D. Perlin, 2008 .

Mutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus pneumoniae

J. Blondeau, K. Drlica, G. Hansen, 2003, Antimicrobial Agents and Chemotherapy.

Dimethyl Sulfoxide Protects Escherichia coli from Rapid Antimicrobial-Mediated Killing

Xilin Zhao, K. Drlica, Yuzhi Hong, 2016, Antimicrobial Agents and Chemotherapy.

Resveratrol Antagonizes Antimicrobial Lethality and Stimulates Recovery of Bacterial Mutants

Xilin Zhao, K. Drlica, Yuzhi Hong, 2016, PloS one.

Involvement of Holliday Junction Resolvase in Fluoroquinolone-Mediated Killing of Mycobacterium smegmatis

Xilin Zhao, K. Drlica, Jianping Xie, 2014, Antimicrobial Agents and Chemotherapy.

Induction of Mycobacterial Resistance to Quinolone Class Antimicrobials

B. Kreiswirth, Xilin Zhao, K. Drlica, 2012, Antimicrobial Agents and Chemotherapy.

Superoxide protects Escherichia coli from bleomycin mediated lethality.

K. Drlica, R. Burger, 2009, Journal of inorganic biochemistry.

Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus.

J. Blondeau, Xilin Zhao, K. Drlica, 2003, The Journal of antimicrobial chemotherapy.

Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.

P. Charles, K. Drlica, L. Piroth, 2004, The Journal of infectious diseases.

Mutant Prevention Concentration-Based Pharmacokinetic/Pharmacodynamic Indices as Dosing Targets for Suppressing the Enrichment of Levofloxacin-Resistant Subpopulations of Staphylococcus aureus

Xilin Zhao, K. Drlica, Rui Wang, 2011, Antimicrobial Agents and Chemotherapy.

Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones

Xilin Zhao, K. Drlica, H. Hiasa, 2016, Nucleic acids research.

Comparison of In Vitro Activities of Fluoroquinolone-Like 2,4- and 1,3-Diones

K. Drlica, H. Hiasa, R. Kerns, 2010, Antimicrobial Agents and Chemotherapy.

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.

J. Blondeau, K. Drlica, C. Hesje, 2015, The Journal of antimicrobial chemotherapy.

Antimicrobial Resistance and Implications for the Twenty-First Century

I. Fong, K. Drlica, 2008 .

Fluoroquinolone-Gyrase-DNA Cleaved Complexes.

K. Drlica, Gan Luan, 2018, Methods in molecular biology.

Minimising moxifloxacin resistance with tuberculosis.

B. Kreiswirth, Xilin Zhao, K. Drlica, 2008, The Lancet. Infectious diseases.

In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.

K. Drlica, T. Lu, 2003, The Journal of antimicrobial chemotherapy.

Glutamine is required for M1-like polarization in response to Mycobacterium tuberculosis infection

I. Kurland, Y. Qiu, K. Drlica, 2022, bioRxiv.

DNA supercoiling in a thermotolerant mutant ofEscherichia coli

K. Drlica, S. Friedman, M. Malik, 1995, Molecular and General Genetics MGG.

Contribution of Reactive Oxygen Species to Thymineless Death in Escherichia coli

Liping Li, Xilin Zhao, K. Drlica, 2017, Nature Microbiology.

DNA gyrase, topoisomerase IV, and the 4-quinolones

K. Drlica, Xilin Zhao, K. Drlica, 1997, Microbiology and molecular biology reviews : MMBR.

Quorum-sensing agr system of Staphylococcus aureus primes gene expression for protection from lethal oxidative stress

D. Lun, I. Yanai, A. Richardson, 2023, bioRxiv.

Quinolones: Action and Resistance Updated

Xilin Zhao, K. Drlica, H. Hiasa, 2009, Current Topics in Medicinal Chemistry.

Dimethyl Sulfoxide Protects Escherichia coli from Rapid Antimicrobial-Mediated Killing

Xilin Zhao, K. Drlica, Yuzhi Hong, 2016, Antimicrobial Agents and Chemotherapy.

Prokaryotic and eukaryotic chromosomes: what's the difference?

K. Drlica, K. Drlica, A. J. Bendich, 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme.

K. Drlica, K. Drlica, M. Sioud, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Fluoroquinolone-Gyrase-DNA Complexes

Kevin R. Marks, J. Berger, Xilin Zhao, 2014, The Journal of Biological Chemistry.

Quorum-sensing agr system of Staphylococcus aureus primes gene expression for protection from lethal oxidative stress.

D. Lun, K. Drlica, A. Pironti, 2024, eLife.

Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity

K. Drlica, K. Drlica, R. Burger, 1996, Antimicrobial agents and chemotherapy.